CClinicalTrials.gg
Status unknownNCT02554214Updated Sep 18, 2015

Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device

An interventional study of Glafkos drainage device in Glaucoma, sponsored by Rheon Medical SA. Status unknown at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-09-18.

Sponsored by Rheon Medical SA · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Sep 2015), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This will be a prospective, descriptive, mono-center, non-comparative study. A sample of 30 patients who satisfy entry criteria is estimated to be appropriate to provide safety and performance data for this study.

The objectives of the study are to verify the performance and safety of the Glafkos adjustable glaucoma drainage device system. Performance will be measured assessing the possibility to adjust the intra-ocular pressure post-operatively. Safety will be measured by the incidence and severity of adverse events.

The Glafkos device will be implanted in combination with a seton tube. The implant is placed under a scleral flap, in a manner analogous to the ex-Press device (Alcon). The distal end of the draining tube is linked to a seton draining tube, which is linked to a plate placed under the extraocular muscles, creating a filtering space at the orbit (filtering bleb).

02

Conditions studied

  • Glaucoma

Browse trials for

03

In context

Glaucoma

1,818 studies on the registry are indexed under Glaucoma; 231 are open to participants now.

This study's planned enrollment of 30 is below the median of 65 across 1,272 interventional studies indexed under Glaucoma.

Browse Glaucoma studies →

Lead sponsor

Rheon Medical SA is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Patient must be 18 years of age or older.
  2. Patient shall suffer from primary open angle glaucoma, pseudo-exfoliative glaucoma, or refractory glaucoma after failed previous filtering surgery, in the study eye. Diagnosis is based on glaucomatous optic neuropathy, Shaffer angle greater than 2 as seen on gonioscopy, and visual field defect attributed to glaucoma.
  3. Eye to be treated shall be phakic or pseudophakic with no other active ocular disease or disorder except for incipiens cataract. Prior ophthalmic surgery in the study eye shall have been performed more than 3 months before enrollment in this study.
  4. Patient condition is indicated for primary and secondary filtration surgery.
  5. Presence of ocular hypertension defined as an intraocular corrected pressure (IOP) > 20 mmHg in the study eye, under maximally tolerated medications. The IOP level shall be obtained on 2 consecutive measurements (not taken on the same day) prior to surgery.
  6. Distance Snellen best corrected visual acuity (BCVA) better than 0.6 in the fellow eye.
  7. For the first three subjects the Snellen BCVA in the study eye should be 0.5 or less. In addition, the visual field defined by the Mean Defect (MD) shall be higher than 10 dB.
  8. Optic neuropathy is exclusively attributed to glaucoma.
  9. Patient agreed to sign the written inform consent prior to entering into the investigation.
  10. Patient is able and willing to complete post-operative follow-up requirements.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of neovascular glaucoma, congenital glaucoma.
  2. History of previous intraocular surgery in the study eye referring to but not limited to extraocular muscles (strabismus), corneal transplant, retinal surgery.
  3. Proliferative or severe non-proliferative retinopathy in either eye.
  4. Congenital anomaly of the anterior chamber angle in the study eye.
  5. Optic neuropathy other than glaucoma in the study eye.
  6. Patient with retinal vein occlusion in the study eye.
  7. Patient with retinal artery occlusion in the study eye.
  8. Patient with corneal opacifications or irregularities that may interfere with the optic nerve evaluation or the IOP measurements in the study eye.
  9. Patient with a history of severe eye trauma in the study eye.
  10. Patient with ocular malformations such as microphthalmia in the study eye.
  11. Patient with concurrent inflammatory/infective eye disorder in the study eye.
  12. Patient with any sign of past or present uveitis (anterior/posterior).
  13. Patient with severe systemic disease or disabling conditions such as chronic renal failure, post organ transplants.
  14. Patient participating in another clinical trial or having participated in another clinical trial less than 3 months prior to entering into the investigation.
  15. Patient is pregnant, breast-feeding or unable to make the decision to participate in a clinical investigation (e.g. mentally ill person, mentally handicapped person)
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Glafkos device

    Device: Glafkos drainage device

Interventions

  • DeviceGlafkos drainage device

    Also known as: eyeWatch

06

What researchers measure

Primary outcomes

  1. Number and type of SADE per patient.

    Time frame: 24 months

  2. IOP measurement

    IOP reduced by ≥ 20% or IOP \< 21 mmHg, and no IOP \< 5 mmHg on two consecutive visits after 3 months.

    Time frame: 24 months

Secondary outcomes

  1. Comprehensive biomicroscopy examination

    Anterior and posterior segments examination using a slit-lamp biomicroscope to evaluate the condition of the cornea (epithelium, stroma, endothelium), the anterior chamber, the iris, the lens, the irido-corneal angle (cf. gonioscopy outcome 9), the vitreous body, retinal and optic nerve anatomy (cf funduscopy outcome 7).

    Time frame: day 1, day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24

  2. Assessment of easiness of surgery by surgeon

    scale: 0=very easy to 5=very difficult

    Time frame: day 0

  3. Assessment of easiness of adjustment

    scale: 0=very easy to 5=very difficult

    Time frame: for 24 months

  4. Subjective refraction

    Assessment of the subjective refraction based on trial and error asking using trial lenses to achieve the best corrected visual acuity

    Time frame: day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24

  5. Funduscopy evaluation

    indirect funduscopy using a 90D lens to evaluate the optic nerve anatomy (cup to disk ratio measurement) and the retinal structures

    Time frame: day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24

  6. Snellen BCVA

    Distance (6m) decimal visual acuity after best optical correction was provided

    Time frame: day 7, day 14, day 28, month 2, month 3, month 6, month 12, month 18 and month 24

  7. gonioscopy assessment

    Irido-corneal angle assessment using the Schaffer grading scale (1-4)

    Time frame: day 7 and day 28

07

Study locations

1 of 1 sites recruiting
  • Montchoisi Clinic
    Lausanne, Vaud 1006, Switzerland
    • André Mermoud, Prof. · Contact · amermoud@gsvn.ch · +4121 619 37 42
    • André Mermoud, Prof. MD. · Principal investigator
    • Sylvain Roy, Dr. MD. · Sub investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02554214
Lead sponsor
Rheon Medical SA
Responsible party
Sponsor
First posted
Sep 18, 2015
Start date
Sep 2015
Primary completion
Sep 2017 (estimated)
Last update
Sep 18, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion